Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aptose Bioscns 251 CONSUMERS ROAD SUITE 1105 TORONTO A6 M2J 4R3 CAN

www.aptose.com P: 64-7479-9828

Description:

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.

Key Statistics

Overview:

Market Capitalization, $K 19,333
Enterprise Value, $K 10,083
Shares Outstanding, K 15,718
Annual Sales, $ 0 K
Annual Net Income, $ -51,210 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,960 K
EBIT, $ -52,360 K
EBITDA, $ -51,890 K
60-Month Beta 1.29
% of Insider Shareholders 9.53%
% of Institutional Shareholders 26.62%
Float, K 14,220
% Float 90.47%
Short Volume Ratio 0.22

Growth:

1-Year Return -83.10%
3-Year Return -98.55%
5-Year Return -96.40%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 41.19%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.44 on 03/26/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -7.72
EPS Growth vs. Prev Qtr 18.18%
EPS Growth vs. Prev Year 12.68%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 06/06/23

APTO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -458.70%
Return-on-Assets % -205.30%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.19
Interest Coverage -2.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar